Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wish people would stop undercutting the bid and ask and let the thing run. You're only cutting your own throat. Give it some time to perculate!! Just my opinion!
I hear ya. I checked my account to see if I was the lucky one. I have some for sale at .27,.39, and 50's
wrong board, evso is not here. This is mcln!! thankyou very much
This is the 5th post since Jan 6th! I guess no one even wants to P & D this one any more, let alone nothing from the company that was supposed to become such a player in home business!! What a POS!!! Thanks small cap society for that great pick!!
What we need is a REAL power hour with some volume to push us up over that .025 and get us moving!
They just dont want to let it run. Buyers were there, and they just kept lowering bid and ask and selling below both. Is that legal?
Definately undervalued, imo, but something is definately up. Over 12 million traded and nearing .23. I think people also realized the value potential in this, especially at these bargain prices. Another scenario could be those who helped run it to 50's could be back to run it again! Too many things going on behind the scenes, but it would be nice to be a fly on the wall during 1 of their board meetings! GLA
Tell me we are not being manipulated. When the bid is higher than the ask and no trades go off, it tells me they are doing everything they can to keep it from moving up! Does anyone have any info they can share on this type of action. TIA
Dude you crack me up. One minute it's doom and gloom, and the next you are making charts and predictions of grandeur!! Glad to have you on board, although I like to see the positive side more than the negative. Good luck to you and yours. In time, MCLN, in my opinion, can make a lot of people a lot of money. Be patient, and lock these shares away and come back in 3-6 months and see where we're at. I can almost guarantee we wont be at 3 cents. Just my opinion!
Steveooo, i sent them an email and here is their reply:
Thank you for your interest in MedClean.
MedClean has not yet announced a date for their Q4 results. Their fiscal year ends 12/31, so this is the annual audit and the form 10-KSB (as opposed to 10-QSB) so the review and audit process is a bit longer. As such, all public companies have 90 days following the end of their fiscal year to announce results. Accordingly, most 12/31 fiscal year ending companies announce results in mid to late March.
As you may know, much of this timeline is driven by the independent auditors, and their schedule. I currently expect MedClean to announce sometime in late March. If the Company conducts a conference call, which they have not done in the past, we would expect to announce the date, time, and dial-in information for this call approximately one week before. At this point, I have no reason to believe that the Company will do a call, but if conditions warrant, and if there is sufficient information to disclose, we will certainly consider that option. Absent a conference call, I don’t expect there will be any announcement of the date of the earnings, and investors will see a press release when it is finalized and approved, following the audit I described earlier.
In addition, it would be a selective disclosure for the company to tell a single shareholder the date for their earnings call without telling all shareholders, so we will not be able to provide interim updates on this matter.
If you have any questions, please feel free to call.
Jeff Stanlis
Partner
Hayden Investor Relations (HIR)
(602) 476-1821
(602) 358-7862 (fax)
jeff@haydenir.com
www.twitter.com/HaydenIR
glty, should get filled with no prob, but then again, you never know
thats what i see. bid is .022, ask is .023, volume 15k
Heres their reply:
Thank you for your interest in MedClean.
MedClean has not yet announced a date for their Q4 results. Their fiscal year ends 12/31, so this is the annual audit and the form 10-KSB (as opposed to 10-QSB) so the review and audit process is a bit longer. As such, all public companies have 90 days following the end of their fiscal year to announce results. Accordingly, most 12/31 fiscal year ending companies announce results in mid to late March.
As you may know, much of this timeline is driven by the independent auditors, and their schedule. I currently expect MedClean to announce sometime in late March. If the Company conducts a conference call, which they have not done in the past, we would expect to announce the date, time, and dial-in information for this call approximately one week before. At this point, I have no reason to believe that the Company will do a call, but if conditions warrant, and if there is sufficient information to disclose, we will certainly consider that option. Absent a conference call, I don’t expect there will be any announcement of the date of the earnings, and investors will see a press release when it is finalized and approved, following the audit I described earlier.
In addition, it would be a selective disclosure for the company to tell a single shareholder the date for their earnings call without telling all shareholders, so we will not be able to provide interim updates on this matter.
If you have any questions, please feel free to call.
Jeff Stanlis
Partner
Hayden Investor Relations (HIR)
(602) 476-1821
(602) 358-7862 (fax)
jeff@haydenir.com
www.twitter.com/HaydenIR
Maybe your reputation preceeds you. I got a response from them in 2 days. Actually, I received responses from 2 different people just from sending them 1 email. Come back in a month, youll be much happier, and so will the rest of us!
Heres what I found on nasdaq.com, looks like 3 trades this am:
A.P. Pharma, Inc. (APPA) Pre-Market Trading
A.P. Pharma, Inc.
Feb. 25, 2010 Market Close: $ 1.90 Get pre-market quotes on-the-go. Introducing NASDAQ Mobile: Simply enter mobile.nasdaq.com into your smartphone's browser.
Learn more about the Pre-Market trading session.
Pre-Market Trade Reporting
Pre-Market Charts | After Hours Charts Pre-Market
Last: $ 2.01 Pre-Market
High: $ 2.29
Pre-Market
Volume: 1,950 Pre-Market
Low: $ 2.01
Trade Detail
Pre-Market
Time (ET) Pre-Market
Price Pre-Market
Share Volume
09:12 $ 2.01 200
09:12 $ 2.01 250
09:09 $ 2.29 1,500
1
4 man show? How about a 2 man! If you ever watched the movie: "Pirates of Silicon Valley", then you would know that Bill Gates, who got his original ideas and stole them from Steve Jobs, started in a run down garage, and look at Microsoft now! I agree with you, it doesnt matter how many people you have, it is the quality of the people that matters. Whether its 2 people or 3 or 4 or whatever, if they have the brains and motivation to succeed, they can. Just My Opinion! GLTA
TTXX, glad to see you being positive! Negativity breeds negativity, so being positive on the board, especially for any visitors or new people to the board, could bring more interest and more investors to MCLN! This can only help those of us who believe in this company! Just my opinion!
Here is the full article I was emailed this morning:
NEWS RELEASE
Contact:
Gavin de Windt
CEL-SCI Corporation
(703) 506-9460
CEL-SCI STUDY SHOWS CEL-2000 vaccine BLOCKS PROGRSSION OF Rheumatoid arthritis
Statistically Significant Findings Published in Prestigious Journal of International Immunopharmacology
Vienna, VA, February 22, 2010 - CEL-SCI Corporation (NYSE AMEX: CVM) and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model. The results were published in the scientific peer-reviewed Journal of International Immunopharmacology (online edition) in an article titled "CEL-2000: A Therapeutic Vaccine for Rheumatoid Arthritis Arrests Disease Development and Alters Serum Cytokine / Chemokine Patterns in the Bovine Collagen Type II Induced Arthritis in the DBA Mouse Model" with lead author Dr. Daniel Zimmerman. The study was co-authored by scientists from CEL-SCI, Washington Biotech, Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOMP) and Boulder BioPath.
CEL-2000, administered after disease (RA) symptoms had started, prevented, in a statistically significant manner, the further development of arthritic conditions, including joint swelling and deformation, bone and cartilage changes and was accompanied by serum cytokine alterations over the CEL-2000 treatment period with comparable or better activity than the well accepted etanercept (Enbrel®) therapy. The mode of action is very consistent with the findings of induction of IL-12 followed by interferon gamma and an inhibition of TNF-alpha and IL-17 production. TNF-alpha and IL-17 are both key cytokines for induction of the pathology seen in rheumatoid arthritis and TNF-alpha is the target of many current RA therapies such as Enbrel, Remicaid, and Humaria. The protection effect mediated by CEL-2000 treatment against RA was also demonstrated histologically with significant reductions in: 1) inflammation, 2) cartilage destruction, 3) bone resorption, and 4) pannus membrane formation in the synovial space compared to untreated controls.
Geert Kersten, Chief Executive Officer of CEL-SCI said, "These experimental results were achieved through a reduction of the inflammatory response that is known to attack the patients' joints. The mode of action of CEL-2000 in RA appears to be similar to our new investigational therapy for H1N1 hospitalized patients, as it attempts to avoid the excess TNF-alpha and other pro-inflammatory cytokines. We feel that this new data is encouraging both for this rheumatoid arthritis vaccine as well as in support of our H1N1 treatment currently under development."
In these studies, mice were injected with collagen to induce the autoimmune (RA) disease. Therapy with Enbrel or CEL-2000 was initiated after disease (RA) symptoms have been established and treatment continued for 28 days after the initiation of a significant, uniform, and measurable level of arthritic disease in groups of mice. CEL-2000 was administered only twice, however Enbrel had to be administered every other day for the 28 day study period (as indicated for Enbrel use). The extent of disease, as measured by deformation of foot joints (Arthritic Index (AI) score), of untreated animals and any improvements resulting from CEL-2000 and Enbrel treated animal were then compared. In another study, CEL-2000 was administered 5 times over a 70 day period and the animals were monitored for a total study period of 90 days. In each case, CEL-2000 treatment proved effective in blocking progression of disease (RA) with statistically significant reduction in AI score compared to controls. The CEL-2000 treatment was deemed safe and well tolerated without any reported adverse effects related to treatment.
The CEL-2000 treatment appeared to change the course of the immune response in the diseased (RA) animals, limiting the development of the destructive action of Th17 and tumor necrosis factor alpha (TNF-alpha). Analysis of serum levels of 21 cytokines/chemokines after 10 days of CEL-2000 treatment indicated reductions in the characteristic cytokine markers of rheumatoid arthritis, TNF-alpha and IL-17, as well as IL-6, and MCP-1. A number of cytokine changes were also seen with Enbrel treatment, but to a lesser degree than that seen with CEL-2000 treatment.
CEL-2000 may also offer a number of potential advantages over existing rheumatoid arthritis treatments, such as Enbrel. Data collected in the animal studies conducted with CEL-2000 demonstrated that CEL-2000 is an effective treatment against rheumatoid arthritis even with administration of many fewer treatments than for example Enbrel. CEL-2000 is also potentially a more disease-type specific therapy, should be significantly less expensive to manufacture, and finally, CEL-2000 could also be useful for patients who are not able to take or who may be unresponsive to other existing anti-arthritis therapies.
This research featured the multidisciplinary team of collaborators bringing to the project expertise of several different animal models of arthritis (Washington Biotech), long time association with modern molecular therapies and evaluation for RA (Bolder Biopath), experience with other LEAPS immunogens, and experience and expertise studying cytokines and with mechanistic studies of the LEAPS technology (NEOUCOMP), and peptide technologies (21st Century Biochemicals) to complement the expertise of the CEL-SCI researchers.
Rheumatoid arthritis treatments comprise an approximately $13 billion market. Enbrel, a leading rheumatoid arthritis treatment sold by Amgen and Wyeth, reported US sales in 2007 of about $3.2 billion. Enbrel is a soluble recombinant protein of a human TNF-alpha receptor linked to human IgG Fc. In some cases, human or humanized monoclonal antibodies specific against TNF-alpha have also been used for therapy in rheumatoid arthritis. These therapies remove or inactivate TNF-alpha, a natural human cytokine required in many immune functions for normal defenses.
CEL-SCI's rheumatoid arthritis vaccine CEL-2000 was discovered as part of work with the Company's ongoing research and development activities with its L.E.A.P.S.â„¢ (Ligand Epitope Antigen Presentation System) technology. L.E.A.P.S. is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology.
The concept behind the L.E.A.P.S. technology is to directly mimic cell-cell interactions and activate immune cells with synthetic peptides. The L.E.A.P.S. constructs containing the antigenic disease epitope linked to a immune-cell binding ligand (ICBL) can be manufactured by peptide synthesis or by covalently linking the two peptides. Depending upon the type of L.E.A.P.S. construct and ICBL used, CEL-SCI is able to direct the outcome of the immune response towards the development of T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). Therefore, it would appear that the L.E.A.P.S. construct represents a chimeric peptide with bi-functional behavior.
Additional details including the full publication with color photomicrographs of tissue sections, tables and figures are available at http://dx.doi.org/10.1016/j.intimp.2009.12.016.
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its L.E.A.P.S. technology platform. The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. This investigational treatment is currently being tested in a clinical study at Johns Hopkins University. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2009. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Seems to me, and this is just my opinion on what ive seen over time with this one, that every time we get some good news, which should peak interest for new investors, the shorts jump right on it and bring it back down to earth. If you put aside the bashers, and the impatient investors who are only looking for quick scores, anyone with half a brain can see their technology is not something to be overlooked. They will only get stronger over time, and time is the key with this one, because they sure seem to take their good ole time with everything they do, including keeping us informed. I sent them an email last week, maybe week before, telling them that they need to be aware of investors who were considering filing complaints with sec, doubting the companies integrity and honesty, etc, and it seems since Ive sent that email, they seem to be communicating a little more with us. Is it a result of emails they received, or just coincidence? Who knows, but I feel, in time, a lot of money can be made in this company if you have the patience and kahonies to stick it out. All is JMHO, but I believe in time, people will say"I remember when this was trading sub-$1.00, and I could of and should of bought a ton of it. Im glad I wont be the 1 saying that!! GLTA
Since so many talk about the earnings release, here is the Earnings Info from Hayden that I received when I emailed them:
Thank you for your interest in MedClean.
MedClean has not yet announced a date for their Q4 results. Their fiscal year ends 12/31, so this is the annual audit and the form 10-KSB (as opposed to 10-QSB) so the review and audit process is a bit longer. As such, all public companies have 90 days following the end of their fiscal year to announce results. Accordingly, most 12/31 fiscal year ending companies announce results in mid to late March.
As you may know, much of this timeline is driven by the independent auditors, and their schedule. I currently expect MedClean to announce sometime in late March. If the Company conducts a conference call, which they have not done in the past, we would expect to announce the date, time, and dial-in information for this call approximately one week before. At this point, I have no reason to believe that the Company will do a call, but if conditions warrant, and if there is sufficient information to disclose, we will certainly consider that option. Absent a conference call, I don’t expect there will be any announcement of the date of the earnings, and investors will see a press release when it is finalized and approved, following the audit I described earlier.
In addition, it would be a selective disclosure for the company to tell a single shareholder the date for their earnings call without telling all shareholders, so we will not be able to provide interim updates on this matter.
If you have any questions, please feel free to call.
Jeff Stanlis
Partner
Hayden Investor Relations (HIR)
(602) 476-1821
(602) 358-7862 (fax)
jeff@haydenir.com
www.twitter.com/HaydenIR
Culley said "within 2 weeks or so", so we should be getting close!
True, but what they dont realize, which is something that always happens to me, is that when they sell to break even or even make a little profit on a quick runup like this, is that normally alot more is just around the corner. I dont know how many times I said if it just gets back to here and i can sell to break even, im out, and then sit and watch in the next few days as it doubles or more. Lost out on siri, mcln, trlg, pwrm, and so on. Now is the time to make the big duckeys, not to settle for even! All IMO only!
Would hope its that or even the fda news, but looks like the dam shorts jumped right back on it and doing everything they can to keep it from running.
wish they would stop undercutting the ask and hold strong, we could really make a move if the peeps would stop doing it and just let it run a little. Should hit close to .40, imo, then jump when we have confirmation of the news!
I see that increased volume. I sure hope its leakage, and then we get to watch the shorts run for cover.
Do you think we have someone in the know, maybe somethings about to happen and there was a little leakage?
what board is yours? I see you refer to it often. tia
Following this for a year or so, I would not be surprised to see it down around .04-.05 range again. Rode this up a couple times already, and if it gets to those levels again, I will definately jump back in and ride it up again. Last time rode it from .045 to .17, although I sold too quick and it went up into low .20's. Just need to have patience after buying, it takes a while untill it moves like that. Just an FYI! Good luck.
They were deleted posts, it will correct itself in time
Not at all. I havent filed a complaint yet, I want to see if they respond. Then I will decide if its worth filing one or not.
Here is the email I sent to CVM today to stir the pot a little. Lets see if I get a response! You can send an email to them at feedback@cel-sci.com
I am just letting you know as a concerned shareholder what is being prepared against you. There are alot of angry shareholders, myself included, that feel very betrayed and lied to by your company and CEO. You have been getting rich yourselves while passing off half truths about the company and its progress with multikline, your facility, and so on. People buy shares in a company because of what they believe is to be honest and truthful statements from the company and its pr firm. But you have been stringing investors along for a couple years now and this is why it has come to this. It can be stopped, but you as a company need to come out and be honest with the shareholders and the public. I can help to stop this massive lawsuit by sharing information and your response with our group. If you choose not to respond, we will continue forward with what we need to do to recover all monies we have lost due to the obvious lies and manipulation by your company and its associates. Good Day!
Below is the website to file a complaint with the Securities and Exchange Commission
*******There is a list of reasons to choose from: I believe what I would like investigated is the validity to their press releases. Have them explain why their pps is going down as pr's are being released. Furthermore, I would like the CEO to provide validity to his video that was released in 2007.
http://www.sec.gov/complaint/selectconduct.shtml
Up until the past week or so, I have been very positive on this stock! But in reading other boards as well as this one, it seems like Cel-Sci is all about themselves as I watch the share price continually drop. There is no way if they are this close to production of multikline that this should be happening. They have been dragging us along for a couple years, taking their good old time in getting things done and it seems like they are just breeding frustration among the shareholders, especially the ones who believe in their technology. Im not a basher, but I am getting really tired of seeing red, and trying to remain positive is getting harder by the day! Sorry if Im babbling.
If you had a sell in at .0004, I wonder why it didnt sell last week when it ran to .00075? Dam MM'S!!!
Stock manipulation! I just needed to vent a little, as I believed in this company, and it just seems like they put out just enough info to keep you believing, then pull the rug out. Its too bad they have let it come to this, 50 cents a share?
Really considering contacting an attorney about this one. What a joke! Anybody say class action lawsuit!
If you look back at my earlier posts, at least 3 times I have posted an email from Hayden stating he expects them to announce in March! Just an FYI!
he said within 2 weeks or so!
The most popular(stillbirth) has 5420 votes. Cobroxin using cobra venom is up to 1660 votes, and is the most popular under alternative medicine, and no show yet. If we want to get noticed, we need a lot of votes and alot more emails to them and comments on their site. I believe it can be done, if peeps take it seriously and go that extra mile. It can only help to get this the attention it deserves! IMO only! Here is the link to the most popular topic right now:
http://www.thedoctorstv.com/produce/vote?sug_archive=no&sug_cat=-all-&sug_sort=thumbs
within 2 weeks or so is what he said
Just voted. Up to 150 now!! Good idea, as we did it for cobroxin as well. We shall see if we can get them to do a show on it!!